Comparing Erythropoietin, Darbepoetin and No Erythropoiesis-Stimulating Agent Treatment in Preventing Anemia of Prematurity: A Multi-Center Retrospective Study
4 affiliations
- 1Neonatal Intensive Care Unit, Kaplan Medical Center (Clalit Health Services), Rehovot 76100, Israel
- 2Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112102, Israel
- 3Neonatal Intensive Care Unit, Meir Medical Center (Clalit Health Services), Kfar Saba 4428163, Israel
- 4Pharmacy Services, Kaplan Medical Center (Clalit Health Services), Rehovot 76100, Israel
Abstract
Objectives: To compare the effects of two different erythropoiesis-stimulating agents [ESAs] and no treatment on the number of blood transfusions and hematocrit [Hct] level. Methods: A retrospective study. Kaplan Medical Center provided data on ESA-treated infants, comparing erythropoietin [EPO] given per protocol until 2018 and darbepoetin [DPO] given from 2018 onwards. Meir Medical Center’s data formed the control group. Data regarding ESA treatment were extracted from a computerized prospective database. A comparison of Hct levels at birth, 14 days of age, 1 month and before discharge and number of blood transfusions received during hospitalization was performed. Mean and standard deviation or median and interquartile range were used for continuous variables and frequency tables for categorical variables. Results: In total, 248 premature infants born between 2016 and 2021 under 1250 g, who survived beyond two weeks of age, were included. No significant differences were found between the EPO and DPO groups in terms of number of blood transfusions or Hct values. The control group received more blood transfusions after two weeks of age [0.8 ± 1.5 vs. 0.5 ± 1.2, p-value = 0.02]. In the treated group, higher Hct values were observed at one month of age [29.9 ± 4.2 vs. 37.9 ± 5.3, p-value < 0.01] and at discharge [29.7 ± 3.8 vs. 34.1 ± 4.6, p-value < 0.01] compared to the control group. Conclusions: ESA treatment was associated with higher hematocrit levels, and no significant differences in efficacy were found between EPO and DPO.
Related
- Early erythropoiesis‐stimulating agents in preterm or low‐birthweight infants
- Vitamin B6 deficiency as a cause of erythropoietin-stimulating agent-resistant anemia in hemodialysis patients: A report of two cases
- Health technology assessment of long-acting erythropoiesis-stimulating agents for the treatment of renal anemia in China
- Elevated Anti-Cytomegalovirus IgG Levels Are Associated with Higher Erythropoiesis-Stimulating Agent Dose in Transplant-Listed Patients with End-Stage Kidney Disease
- Neonatal hyperglycemia as an independent risk factor for retinopathy of prematurity: a multicenter retrospective cohort study with dose-response analysis
BibTeX
@article{gadassi2026comparing,
title = {{Comparing Erythropoietin, Darbepoetin and No Erythropoiesis-Stimulating Agent Treatment in Preventing Anemia of Prematurity: A Multi-Center Retrospective Study}},
author = {Noa Gadassi and Sivahn Goldstein and Michal Wulkan and Eynit Grinblatt and Dotan Shaniv and Shay Teitlboim and Calanit Hershkovich Shporen},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15218251},
url = {https://www.mdpi.com/2077-0383/15/21/8251},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Comparing Erythropoietin, Darbepoetin and No Erythropoiesis-Stimulating Agent Treatment in Preventing Anemia of Prematurity: A Multi-Center Retrospective Study
AU - Noa Gadassi
AU - Sivahn Goldstein
AU - Michal Wulkan
AU - Eynit Grinblatt
AU - Dotan Shaniv
AU - Shay Teitlboim
AU - Calanit Hershkovich Shporen
PY - 2026
DA - 2026/10/23
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218251
UR - https://www.mdpi.com/2077-0383/15/21/8251
AB - Objectives: To compare the effects of two different erythropoiesis-stimulating agents [ESAs] and no treatment on the number of blood transfusions and hematocrit [Hct] level. Methods: A retrospective study. Kaplan Medical Center provided data on ESA-treated infants, comparing erythropoietin [EPO] given per protocol until 2018 and darbepoetin [DPO] given from 2018 onwards. Meir Medical Center’s data formed the control group. Data regarding ESA treatment were extracted from a computerized prospective database. A comparison of Hct levels at birth, 14 days of age, 1 month and before discharge and number of blood transfusions received during hospitalization was performed. Mean and standard deviation or median and interquartile range were used for continuous variables and frequency tables for categorical variables. Results: In total, 248 premature infants born between 2016 and 2021 under 1250 g, who survived beyond two weeks of age, were included. No significant differences were found between the EPO and DPO groups in terms of number of blood transfusions or Hct values. The control group received more blood transfusions after two weeks of age [0.8 ± 1.5 vs. 0.5 ± 1.2, p-value = 0.02]. In the treated group, higher Hct values were observed at one month of age [29.9 ± 4.2 vs. 37.9 ± 5.3, p-value < 0.01] and at discharge [29.7 ± 3.8 vs. 34.1 ± 4.6, p-value < 0.01] compared to the control group. Conclusions: ESA treatment was associated with higher hematocrit levels, and no significant differences in efficacy were found between EPO and DPO.
SN - 2077-0383
ER -